Neural Therapeutics Inc. · CSE:NURL
Neural Therapeutics — Investor Presentation (July 2023)
31 slides from Neural Therapeutics's investor presentation, July 2023
Slide 1: Neural Therapeutics Inc. Corporate Presentation
Neural Therapeutics Inc. Corporate Presentation July 2023
Slide 2: Disclaimer and Forward-Looking Statements
Disclaimer and Forward-Looking Statements CONFIDENTIAL INFORMATION NOT AN OFFER This presentation (the “Presentation"), inclusive of all materials and information provided herewith This Presentation does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any s
Slide 3: Disclaimer and Forward-Looking Statements (cont.)
Disclaimer and Forward-Looking Statements (cont.) FORWARD LOOKING STATEMENT AND RISK FACTORS Certain statements contained in this Presentation relate to the historical experience of our founders, management team This Presentation includes certain “forward-looking information” and “forward-looking st
Slide 4: Psychedelics are gaining significant momentum
Psychedelics are gaining significant momentum Three major industry catalysts announced since our last fireside chat: May 2nd the American Medical Association announced new billing codes for psychedelic therapies upon regulatory approval June 23rd FDA Issues First Draft Guidance on Clinical Trials wi
Slide 5: Executive Overview
Executive Overview • Neural Therapeutics Inc. is a life sciences company focused on the research and development of compounds from psychoactive plants. • Our first target is mescaline from the San Pedro cactus (Echinopsis pachanoi or Trichocereus pachanoi) • Peer-reviewed and historical scientific l
Slide 6: About Psychedelic Cacti
About Psychedelic Cacti Indigenous/Native populations have used Peyote and San Pedro as botanical medicines for millennia Contains the highest concentration of Mescaline – around 3 to 6% of Despite the lower mescaline the dried weight concentration at around 1 - 4.5%, San Pedro Cactus the larger mas
Slide 7: History of Mescaline
History of Mescaline Mescaline has been widely used throughout our history Mescaline is found in the fast- Dr. John Raleigh Briggs wrote German pharmacologist and physicist Failure of Mescaline to solve the growing San Pedro cactus and the about his experience after eating Arthur Heffter isolated th
Slide 8: Advantages: Plant-Derived Mescaline
Advantages: Plant-Derived Mescaline Journal of Psychopharmacology reported improvement in anxiety and depression by > 67% of respondents who ingested plant sourced Mescaline Mescaline Isolation and Purification ❖ Precedent: Epidiolex/EpidyolexTM, purified cannabidiol derived from plant and manufactu
Slide 9: Market Stats - Pharmaceutical
Market Stats - Pharmaceutical $70+ billion total market Institutional Market Momentum ADHD: $29.6 Billion Smoking Cessation: $23.4 Billion Depression*: $12.1 Billion Substance Abuse Treatment*: $16.5 Billion • Veterans of War & Heroic Hearts Project: non-profits that connect military veterans strugg
Slide 10: Mescaline: Neural Therapeutics Advantage
Mescaline: Neural Therapeutics Advantage A holistic approach to the plant Historical Use: Mescaline from cacti has been used for at least 5,700 years(1) throughout North America Safety: Mescaline requires larger doses vs. other psychedelics to achieve hallucinogenic effects Use in Therapy: Mescaline
Slide 11: R&D Targeted Near-Term Objectives – Pharmaceutical and Nutraceutical
R&D Targeted Near-Term Objectives – Pharmaceutical and Nutraceutical Supply Chain: Expect to have cGMP supply chain agreement complying with US FDA standards by Q1 Partners: Expect CROs selection by year end, to conduct pre-clinical and clinical studies according to ICH, GLP and GCP guidelines (for
Slide 12: Research & Development Pathway
Research & Development Pathway Pharmaceutical Development • Pre-Clinical Studies: Create a formulation(s) that can be tested in IND- enabling studies Supply Chain Permits and Studies • Clinical Studies: Conduct Phase I – III clinical trials (after regulatory approval) $70+ Optimizing Extraction Gov.
Slide 13: Past Milestones
Past Milestones Company Acquisition by CRO engaged for Comprehensive Engaged Additional CROs Peru is selected as the Identify New Management Successfully Formed. Nutritional High initial North Mescaline Research regulatory and legal advisors location of focus of the sources of Team, Board of closed
Slide 14: Recent Developments
Recent Developments Legal Spin-out Peruvian permit genetic National Partner for SERFOR and Patent application Cactus Cultivation Completed – May 23rd study of flora and Service Contract established with submitted - a novel Experiment harvesting of wild plants Cayetano University: Plant method of ext
Slide 15: Purpose: Neural Therapeutics
Purpose: Neural Therapeutics Vamvakopoulou IA, Narine KAD, Campbell I, Dyck JRB, Nutt DJ. Mescaline: The forgotten psychedelic. Neuropharmacology. 2022 Oct 14:109294. doi: 10.1016/j.neuropharm.2022.109294. Epub ahead of print. PMID: 36252614. 15
Slide 16: 2023: Off to a Great Start – More to Come
2023: Off to a Great Start – More to Come Chemistry: Extraction optimization and chemical characterization and clinical assays Production: Scaling-up from bench to large batch production Supply Chain: Access to greenhouse cultivation experts, labelling and export assistance Advancing Human Trial Dat
Slide 17: Current & Future Milestones and Objectives
Current & Future Milestones and Objectives Q2 2022 Q3-Q4 2022 Q1-Q2 2023 2023-2024 ➢ Commenced preliminary ➢ Secure all necessary permits for ➢ Cactus extraction study and SOP ➢ IP-Extraction and formulations scientific studies initial drug related R&D defined defined ➢ IP - Commenced ➢ Initiate cul
Slide 18: Pro-Forma Capitalization
Pro-Forma Capitalization Minimum Maximum Offering Offering % Basic(4) % FD(4) ($1.0M)(5) ($2.1M)(5) Shares Currently Issued and Outstanding 39,469,310 39,469,310 35% 29% Series "A" Financings ($0.03 per Common Share) (1)(5) 33,333,333 69,469,310 61% 51% Other (2) 3,640,132 5,446,931 5% 4% Neural Sha
Slide 19: Pro-Forma Ownership and Use of Proceeds
Pro-Forma Ownership and Use of Proceeds Series "A" Investors have a unique opportunity to own a significant piece of a company with significant value catalysts in the pipeline and have their investment dollars directly fund those catalysts. Minimum Offering Maximum Offering Principal Uses of Funds (
Slide 20: Scientific & Impact Advisory Committee
Scientific & Impact Advisory Committee Professor David Nutt – David Nutt is a psychiatrist and the Edmond J. Safra Professor of Neuropsychopharmacology in the Division of Brain Science, Imperial College London. He was previously President of the, European Brain Council, British Association of Psycho
Slide 21: Leadership Team
Leadership Team Ian Campbell, MSc – Chief Executive Officer and Director – Mr. Campbell is an executive leader who has an international reputation for building effective teams, managing operations and product commercialization. He has managed multinational entities residing in the US, Canada as well
Slide 22: Contact Information
Contact Information Ian Campbell, CEO Neural Therapeutics Inc. C: 226-218-2255 E: icampbell@neuraltherapeutics.com 77 King Street West, Suite 2905 Toronto, ON M5K 1H1 23
Slide 23: Appendix
Appendix 24
Slide 24: Sources – Market Statistics
Sources – Market Statistics Pharmaceutical • ADHD: ADHD Therapeutics Market Size, Trends & Growth | 2021 to 2026 (marketdataforecast.com) • Anti-addiction: Addiction Treatment Market Size is Projected to Reach US$ 11 Billion by 2027 – The Market Publicist • Anxiety: Anxiety Disorders and Depression
Slide 25: Additional Sources
Additional Sources Market Statistics – Nutraceutical • Dietary Fat Uptake Reduction: https://pubmed.ncbi.nlm.nih.gov/25067985 • Diabetic Control Benefits of Cacti: Antidiabetic Effect of Fresh Nopal (Opuntia ficus-indica) in Low-Dose Streptozotocin-Induced Diabetic Rats Fed a High-Fat Diet (hindawi.
Slide 26: Neural Therapeutics Philosophy
Neural Therapeutics Philosophy Why we are focusing on mescaline from natural sources, in particular the San Pedro cactus? Mescaline is Different Honoring Ethnobotanical Use ❖ Mescaline has a unique receptor drug affinity and response than ❖ Thousands of years of historical experience is an invaluabl
Slide 27: Mescaline vs. Other Psychedelics
Mescaline vs. Other Psychedelics Typical Psychedelic Molecular Duration of Hallucinogenic Potential Therapeutic Uses Onset of Effects Substance Structure Effects Dose Addiction (e.g., alcohol), Anxiety LSD 0.05 - 0.2 mg 30 - 40 min 8 - 12h associated with terminal illness Addiction (tobacco, alcohol
Slide 28: Market Stats - Nutraceutical
Market Stats - Nutraceutical $175+ billion total market ❖ Benefits: Cacti are high in fiber, antioxidants carotenoids, vitamins Dietary $140 Billion Weight Loss Supplements: $24 Billion and a source of amino + fatty acids Supplements: ❖ Clinical Data: Cacti fiber scavenges dietary fat and reduce obe
Slide 29: Nutraceutical Market Strategy
Nutraceutical Market Strategy The nutraceutical strategy will focus on monetizing the non-mescaline portion of the cactus. Mescaline is not equally distributed throughout San Pedro. It resides mainly in the outer surfaces. Our focus will be to efficiently extract mescaline and other medically benefi
Slide 30: R&D Targeted Deliverables Objectives - Nutraceutical
R&D Targeted Deliverables Objectives - Nutraceutical Focus on extracting benefit from all parts of the cactus plant. ❖ Raw Material: The residual San Pedro solids and extracts separated from mescaline are the raw materials – determine the composition of the parts that have potential therapeutic bene
Slide 31: Snapshot: San Pedro Derived Mescaline – North America
Snapshot: San Pedro Derived Mescaline – North America Evolving laws and regulations to reduce street drug epidemic + provide a pathway to therapeutics Decriminalization/Legalization/Regulation in North America San Pedro: Mescaline and Psychedelics in the US British Columbia (Vancouver): June 1, 2021
Neural Therapeutics — Investor Presentation (July 2023) on 6ix